|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2002-4-16
|
|
pubmed:abstractText |
Atherosclerosis has features of an inflammatory disease. Because cyclooxygenase (COX)-2 is expressed in atherosclerotic lesions and promotes inflammation, we tested the hypotheses that selective COX-2 inhibition would reduce early lesion formation in LDL receptor-deficient (LDLR-/-) mice and that macrophage COX-2 expression contributes to atherogenesis in LDLR-/- mice.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2 Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Indomethacin,
http://linkedlifedata.com/resource/pubmed/chemical/Isoenzymes,
http://linkedlifedata.com/resource/pubmed/chemical/Lactones,
http://linkedlifedata.com/resource/pubmed/chemical/Lipids,
http://linkedlifedata.com/resource/pubmed/chemical/Prostaglandin-Endoperoxide Synthases,
http://linkedlifedata.com/resource/pubmed/chemical/Prostaglandins,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, LDL,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfones,
http://linkedlifedata.com/resource/pubmed/chemical/Thromboxane B2,
http://linkedlifedata.com/resource/pubmed/chemical/rofecoxib
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1524-4539
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
16
|
|
pubmed:volume |
105
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1816-23
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:11956125-Animals,
pubmed-meshheading:11956125-Arteriosclerosis,
pubmed-meshheading:11956125-Blood Platelets,
pubmed-meshheading:11956125-Cyclooxygenase 2,
pubmed-meshheading:11956125-Cyclooxygenase 2 Inhibitors,
pubmed-meshheading:11956125-Cyclooxygenase Inhibitors,
pubmed-meshheading:11956125-Female,
pubmed-meshheading:11956125-Indomethacin,
pubmed-meshheading:11956125-Isoenzymes,
pubmed-meshheading:11956125-Kinetics,
pubmed-meshheading:11956125-Lactones,
pubmed-meshheading:11956125-Lipids,
pubmed-meshheading:11956125-Liver Transplantation,
pubmed-meshheading:11956125-Macrophages,
pubmed-meshheading:11956125-Male,
pubmed-meshheading:11956125-Mice,
pubmed-meshheading:11956125-Mice, Inbred C57BL,
pubmed-meshheading:11956125-Mice, Knockout,
pubmed-meshheading:11956125-Prostaglandin-Endoperoxide Synthases,
pubmed-meshheading:11956125-Prostaglandins,
pubmed-meshheading:11956125-RNA, Messenger,
pubmed-meshheading:11956125-Receptors, LDL,
pubmed-meshheading:11956125-Sulfones,
pubmed-meshheading:11956125-Thromboxane B2
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice.
|
|
pubmed:affiliation |
Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tenn, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
